

Supplementary report Annex C:

Cluster signals identify by AMASS-SaTScan

Hospital name: Hypothetical Hospital

Country name: Hypothetical Country

Data from:

02 Jan 2016 to 31 Dec 2016

This is a detailed report for records with cluster signals identified by the AMASS-SaTScan. This report, together with the full list in Excel format, is for users to check and validate the cluster and the patients in each cluster identified by the SaTScan. The information available in this PDF file include ward names used in the dictionary files.

Generated on: 20 Jun 2025 16:04

Blood specimen: MRSA

Baseline information

No. of patients = 19

No. of wards = 2

No. of AMR profiles = 2

List of AST results

| AST results | Cefoxitin | Oxacillin by MIC | Vancomycin | Clindamycin | Chloramphenicol | Erythromycin | Ofloxacin | Gentamicin | Amikacin | Co-trimoxazole | Rifampicin | Teicoplanin | Daptomycin | Linezolid | Ceftaroline | Piperacillin/tazobactam |
|--------------|-----------|------------------|------------|-------------|-----------------|--------------|-----------|------------|----------|----------------|------------|-------------|------------|-----------|-------------|-------------------------|
| R | 19 | - | 3 | 16 | - | - | - | - | - | - | - | - | - | - | - | - |
| I | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| S | 0 | - | 16 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| NA | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| C1:≥90% | P | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |
| C2:variation | F | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |
| Summary | F | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: MRSA


(No. of patients = 19)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA


Antibiotic : Vancomycin

Proportion of NA = 0% (0/19)



Antibiotic : Clindamycin

Proportion of NA = 0% (0/19)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: MRSA

List of profiles

| Profile ID | Cefoxitin | Oxacillin by MIC | Vancomycin | Clindamycin | Chloramphenicol | Erythromycin | Ofloxacin | Gentamicin | Amikacin | Co-trimoxazole | Rifampicin | Teicoplanin | Daptomycin | Linezolid | Ceftaroline | Piperacillin/tazobactam | No. of patients |
|--------------|-----------|------------------|------------|-------------|-----------------|--------------|-----------|------------|----------|----------------|------------|-------------|------------|-----------|-------------|-------------------------|-----------------|
| MRSA_BL_2 | - | - | S | R | - | - | - | - | - | - | - | - | - | - | - | - | 16 |
| MRSA_BL_1 | - | - | R | S | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: MRSA

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 14 |
| ward_002 | 5 |
| Total | 19 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.


Blood specimen: MRSA

Display of patients with blood culture positive for MRSA in each ward over time

Ward : ward_001



Ward : ward_002



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: MRSA

Baseline information

No. of patients = 56

No. of wards = 2

No. of AMR profiles = 2

List of AST results

| AST results | Cefoxitin | Oxacillin by MIC | Vancomycin | Clindamycin | Chloramphenicol | Erythromycin | Ofloxacin | Gentamicin | Amikacin | Co-trimoxazole | Rifampicin | Teicoplanin | Daptomycin | Linezolid | Ceftaroline | Piperacillin/tazobactam |
|--------------|-----------|------------------|------------|-------------|-----------------|--------------|-----------|------------|----------|----------------|------------|-------------|------------|-----------|-------------|-------------------------|
| R | 56 | - | 3 | 53 | - | - | - | - | - | - | - | - | - | - | - | - |
| I | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| S | 0 | - | 53 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| NA | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| C1:≥90% | P | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |
| C2:variation | F | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |
| Summary | F | - | P | P | - | - | - | - | - | - | - | - | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: MRSA


(No. of patients = 56)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA


Antibiotic : Vancomycin

Proportion of NA = 0% (0/56)



Antibiotic : Clindamycin

Proportion of NA = 0% (0/56)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: MRSA

List of profiles

| Profile ID | Cefoxitin | Oxacillin by MIC | Vancomycin | Clindamycin | Chloramphenicol | Erythromycin | Ofloxacin | Gentamicin | Amikacin | Co-trimoxazole | Rifampicin | Teicoplanin | Daptomycin | Linezolid | Ceftaroline | Piperacillin/tazobactam | No. of patients |
|--------------|-----------|------------------|------------|-------------|-----------------|--------------|-----------|------------|----------|----------------|------------|-------------|------------|-----------|-------------|-------------------------|-----------------|
| MRSA_ALL_2 | - | - | S | R | - | - | - | - | - | - | - | - | - | - | - | - | 53 |
| MRSA_ALL_1 | - | - | R | S | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: MRSA

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 38 |
| ward_002 | 18 |
| Total | 56 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.


All specimens: MRSA

Display of patients with a clinical specimen culture positive for MRSA in each ward over time

Ward : ward_001



Ward : ward_002



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: VREfs

Baseline information

No. of patients = 0

No. of wards = 0

No. of AMR profiles = 0

List of AST results

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: VREfs

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: VREfs

list of profiles

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: VREfs

List of wards

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

Blood specimen: VREfs

Display of patients with blood culture positive for VREfs in each ward over time

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: VREfs

Baseline information

No. of patients = 0

No. of wards = 0

No. of AMR profiles = 0

List of AST results

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: VREfs

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: VREfs

list of profiles

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: VREfs

List of wards

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

All specimens: VREfs

Display of patients with a clinical specimen culture positive for VREfs in each ward over time

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: VREfm

Baseline information

No. of patients = 0

No. of wards = 0

No. of AMR profiles = 0

List of AST results

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: VREfm

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: VREfm

list of profiles

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: VREfm

List of wards

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

Blood specimen: VREfm

Display of patients with blood culture positive for VREfm in each ward over time

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: VREfm

Baseline information

No. of patients = 0

No. of wards = 0

No. of AMR profiles = 0

List of AST results

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: VREfm

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: VREfm

list of profiles

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: VREfm

List of wards

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

All specimens: VREfm

Display of patients with a clinical specimen culture positive for VREfm in each ward over time

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: CREC

Baseline information

No. of patients = 4

No. of wards = 1

No. of AMR profiles = 1

List of AST results

| AST results | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 4 | 4 | - | 4 | 4 | - | - | 4 | 4 | 4 | 4 | 4 | 4 | 4 | - | - | - | - |
| I | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| S | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| NA | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| C1:≥90% | P | P | - | P | P | - | - | P | P | P | P | P | P | P | - | - | - | - |
| C2:variation | F | F | - | F | F | - | - | F | F | F | F | F | F | F | - | - | - | - |
| Summary | F | F | - | F | F | - | - | F | F | F | F | F | F | F | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: CREC

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: CREC

List of profiles

| Profile ID | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CREC_BL_na | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: CREC

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_003 | 4 |
| Total | 4 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

Blood specimen: CREC

Display of patients with blood culture positive for CREC in each ward over time

Ward : ward_003



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: CREC

Baseline information

No. of patients = 12

No. of wards = 1

No. of AMR profiles = 1

List of AST results

| AST results | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 12 | 12 | - | 12 | 12 | - | - | 12 | 12 | 12 | 12 | 12 | 12 | 12 | - | - | - | - |
| I | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| S | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| NA | 0 | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| C1:≥90% | P | P | - | P | P | - | - | P | P | P | P | P | P | P | - | - | - | - |
| C2:variation | F | F | - | F | F | - | - | F | F | F | F | F | F | F | - | - | - | - |
| Summary | F | F | - | F | F | - | - | F | F | F | F | F | F | F | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: CREC

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: CREC

List of profiles

| Profile ID | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CREC_ALL_na | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: CREC

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_003 | 12 |
| Total | 12 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

All specimens: CREC

Display of patients with a clinical specimen culture positive for CREC in each ward over time

Ward : ward_003



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: CRKP

Baseline information

No. of patients = 2

No. of wards = 1

No. of AMR profiles = 1

List of AST results

| AST results | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|
| R | - | 2 | - | 2 | 2 | - | - | 2 | 2 | 2 | 2 | 0 | - | 2 | - | - | - | - |
| I | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - |
| S | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 2 | - | 0 | - | - | - | - |
| NA | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - |
| C1:≥90% | - | P | - | P | P | - | - | P | P | P | P | P | - | P | - | - | - | - |
| C2:variation | - | F | - | F | F | - | - | F | F | F | F | F | - | F | - | - | - | - |
| Summary | - | F | - | F | F | - | - | F | F | F | F | F | - | F | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: CRKP

(No. of patients = 0)

Distribution of patients with AST results for the antibiotics that passed the criteria

None

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: CRKP

List of profiles

| Profile ID | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRKP_BL_na | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: CRKP

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 2 |
| Total | 2 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

Blood specimen: CRKP

Display of patients with blood culture positive for CRKP in each ward over time

Ward : ward_001



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: CRKP

Baseline information

No. of patients = 15

No. of wards = 1

No. of AMR profiles = 2

List of AST results

| AST results | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|
| R | - | 15 | - | 15 | 15 | - | - | 15 | 15 | 15 | 15 | 4 | - | 15 | - | - | - | - |
| I | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - |
| S | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 11 | - | 0 | - | - | - | - |
| NA | - | 0 | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - |
| C1:≥90% | - | P | - | P | P | - | - | P | P | P | P | P | - | P | - | - | - | - |
| C2:variation | - | F | - | F | F | - | - | F | F | F | F | P | - | F | - | - | - | - |
| Summary | - | F | - | F | F | - | - | F | F | F | F | P | - | F | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).


(No. of patients = 15)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA

Antibiotic : Imipenem

Proportion of NA = 0% (0/15)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: CRKP

List of profiles

| Profile ID | Ampicillin | Gentamicin | Amikacin | Co-trimoxazole | Ciprofloxacin | Levofloxacin | Cefpodoxime | Ceftriaxone | Ceftazidime | Cefotaxime | Cefepime | Imipenem | Meropenem | Ertapenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|------------|------------|----------|----------------|---------------|--------------|-------------|-------------|-------------|------------|----------|----------|-----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRKP_ALL_2 | - | - | - | - | - | - | - | - | - | - | - | S | - | - | - | - | - | - | 11 |
| CRKP_ALL_1 | - | - | - | - | - | - | - | - | - | - | - | R | - | - | - | - | - | - | 4 |
| Total | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: CRKP

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 15 |
| Total | 15 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

All specimens: CRKP

Display of patients with a clinical specimen culture positive for CRKP in each ward over time

Ward : ward_001



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: CRPA

Baseline information

No. of patients = 4

No. of wards = 1

No. of AMR profiles = 2

List of AST results

| AST results | Ceftazidime | Ciprofloxacin | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|-------------|---------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 4 | 2 | 4 | - | 4 | 4 | - | - | - | - |
| I | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - |
| S | 0 | 2 | 0 | - | 0 | 0 | - | - | - | - |
| NA | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - |
| C1:≥90% | P | P | P | - | P | P | - | - | - | - |
| C2:variation | F | P | F | - | F | F | - | - | - | - |
| Summary | F | P | F | - | F | F | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: CRPA


(No. of patients = 4)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA

Antibiotic : Ciprofloxacin

Proportion of NA = 0% (0/4)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: CRPA

List of profiles

| Profile ID | Ceftazidime | Ciprofloxacin | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|------------|-------------|---------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRPA_BL_1 | - | R | - | - | - | - | - | - | - | - | 2 |
| CRPA_BL_2 | - | S | - | - | - | - | - | - | - | - | 2 |
| Total | - | - | - | - | - | - | - | - | - | - | 4 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: CRPA

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 4 |
| Total | 4 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

Blood specimen: CRPA

Display of patients with blood culture positive for CRPA in each ward over time

Ward : ward_001



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: CRPA

Baseline information

No. of patients = 28

No. of wards = 1

No. of AMR profiles = 3

List of AST results

| AST results | Ceftazidime | Ciprofloxacin | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|-------------|---------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 21 | 14 | 21 | - | 28 | - | - | - | - | - |
| I | 0 | 0 | 0 | - | 0 | - | - | - | - | - |
| S | 7 | 14 | 7 | - | 0 | - | - | - | - | - |
| NA | 0 | 0 | 0 | - | 0 | - | - | - | - | - |
| C1:≥90% | P | P | P | - | P | - | - | - | - | - |
| C2:variation | P | P | P | - | F | - | - | - | - | - |
| Summary | P | P | P | - | F | - | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: CRPA


(No. of patients = 28)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA


Antibiotic : Ceftazidime

Proportion of NA = 0% (0/28)




Antibiotic : Ciprofloxacin

Proportion of NA = 0% (0/28)



Antibiotic : Gentamicin

Proportion of NA = 0% (0/28)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: CRPA

List of profiles

| Profile ID | Ceftazidime | Ciprofloxacin | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|------------|-------------|---------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRPA_ALL_1 | R | R | R | - | - | - | - | - | - | - | 14 |
| CRPA_ALL_2 | R | S | R | - | - | - | - | - | - | - | 7 |
| CRPA_ALL_3 | S | S | S | - | - | - | - | - | - | - | 7 |
| Total | - | - | - | - | - | - | - | - | - | - | 28 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: CRPA

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_001 | 28 |
| Total | 28 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.

All specimens: CRPA

Display of patients with a clinical specimen culture positive for CRPA in each ward over time

Ward : ward_001



***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Blood specimen: CRAB

Baseline information

No. of patients = 44

No. of wards = 2

No. of AMR profiles = 4

List of AST results

| AST results | Tigecycline | Minocycline | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|-------------|-------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 0 | - | 38 | - | 44 | 39 | - | - | - | - |
| I | 0 | - | 0 | - | 0 | 4 | - | - | - | - |
| S | 44 | - | 6 | - | 0 | 1 | - | - | - | - |
| NA | 0 | - | 0 | - | 0 | 0 | - | - | - | - |
| C1:≥90% | P | - | P | - | P | P | - | - | - | - |
| C2:variation | F | - | P | - | F | P | - | - | - | - |
| Summary | F | - | P | - | F | P | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

Blood specimen: CRAB


(No. of patients = 44)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA


Antibiotic : Gentamicin

Proportion of NA = 0% (0/44)



Antibiotic : Meropenem

Proportion of NA = 0% (0/44)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

Blood specimen: CRAB

List of profiles

| Profile ID | Tigecycline | Minocycline | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|-------------|-------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRAB_BL_2 | - | - | R | - | - | R | - | - | - | - | 34 |
| CRAB_BL_3 | - | - | S | - | - | R | - | - | - | - | 5 |
| CRAB_BL_1 | - | - | R | - | - | I | - | - | - | - | 4 |
| CRAB_BL_4 | - | - | S | - | - | S | - | - | - | - | 1 |
| Total | - | - | - | - | - | - | - | - | - | - | 44 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

Blood specimen: CRAB

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_004 | 43 |
| ward_001 | 1 |
| Total | 44 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.


Blood specimen: CRAB

Display of patients with blood culture positive for CRAB in each ward over time

Ward : ward_004



Ward : ward_001



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with blood culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

All specimens: CRAB

Baseline information

No. of patients = 143

No. of wards = 2

No. of AMR profiles = 4

List of AST results

| AST results | Tigecycline | Minocycline | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam |
|--------------|-------------|-------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|
| R | 0 | - | 135 | - | 143 | 135 | - | - | - | - |
| I | 0 | - | 0 | - | 0 | 4 | - | - | - | - |
| S | 143 | - | 8 | - | 0 | 4 | - | - | - | - |
| NA | 0 | - | 0 | - | 0 | 0 | - | - | - | - |
| C1:≥90% | P | - | P | - | P | P | - | - | - | - |
| C2:variation | F | - | P | - | F | P | - | - | - | - |
| Summary | F | - | P | - | F | P | - | - | - | - |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic. Criteria 1 (C1) is defined as the proportion of isolates with AST data available against the antibiotic being higher than 90%. Criteria 2 (C2) is defined as the presence of variation in AST results (e.g., not 100% R and not 100% S). The summary is marked as P (Pass) when both C1 and C2 are met. Otherwise, it is marked as F (Fail).

All specimens: CRAB


(No. of patients = 143)

Distribution of patients with AST results for the antibiotics that passed the criteria

Labels : R I S NA


Antibiotic : Gentamicin

Proportion of NA = 0% (0/143)



Antibiotic : Meropenem

Proportion of NA = 0% (0/143)



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the proportion of isolates that are resistant (orange bars), intermediate (yellow bars) and susceptible (green bars) to the antibiotic, respectively. NA (Not Available; black bars) represents the number of isolates for which AST data is not available against the antibiotic. Only antibiotics are passed both C1 and C2 are displayed.

All specimens: CRAB

List of profiles

| Profile ID | Tigecycline | Minocycline | Gentamicin | Amikacin | Imipenem | Meropenem | Doripenem | Colistin | Piperacillin/tazobactam | Cefoperazone/sulbactam | No. of patients |
|--------------|-------------|-------------|------------|----------|----------|-----------|-----------|----------|-------------------------|------------------------|-----------------|
| CRAB_ALL_2 | - | - | R | - | - | R | - | - | - | - | 131 |
| CRAB_ALL_1 | - | - | R | - | - | I | - | - | - | - | 4 |
| CRAB_ALL_3 | - | - | S | - | - | R | - | - | - | - | 4 |
| CRAB_ALL_4 | - | - | S | - | - | S | - | - | - | - | 4 |
| Total | - | - | - | - | - | - | - | - | - | - | 143 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. **The first AMR isolate** per patient per evaluation period is included in the AMASS-SaTScan analysis. R, I and S represent the number of isolates that are resistant, intermediate and susceptible to the antibiotic, respectively. NA (Not Available) represents the number of isolates for which AST data is not available against the antibiotic. - is used when no AST data is available for any of the isolates against the antibiotic.

All specimens: CRAB

List of ward


| Ward ID | No. of patients |
|--------------|-----------------|
| ward_004 | 139 |
| ward_001 | 4 |
| Total | 143 |

***Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3).** The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization.


All specimens: CRAB

Display of patients with a clinical specimen culture positive for CRAB in each ward over time

Ward : ward_004



Ward : ward_001



*Please note that the patients included in the analysis for cluster signals (Annex C) were not exactly similar to those included in the analysis for the AMR proportion report (Section 2-3). The AMASS-SaTScan (Annex C) included patients who had a specimen culture positive for the AMR pathogen of interest, with the first culture-positive specimen collected after the first two calendar days of hospitalization. Bar graphs show patients with a clinical specimen culture positive with the organism with a profile identified in at least one cluster signal. Gray bars (Other profiles) represents patients with blood culture positive for organisms with profiles that were not included in any cluster signals. Only wards with a cluster signal identified or having the top three highest number of patients are displayed.

Table S1: List of ward names in your microbiology_data file

List of ward

| Ward ID | Ward name |
|----------|---------------------|
| ward_001 | male medical ward 1 |
| ward_002 | ICU med. |
| ward_003 | male medical ward 2 |
| ward_004 | female medical ward |
| ward_005 | female surgery ward |
| ward_006 | male medical ward 3 |

* In case that there are ward names in your hospital_admission_data file, this list and the analysis will prioritize the ward names in the microbiology_data file over the ones in hospital_admission_data file.